BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

about

Linked CD4 T Cell Help: Broadening Immune Attack Against Cancer by Vaccination.Conference scene: Immune signatures in the tumor and beyond.

P2860

Q49013708-33C823DE-DBFD-4425-B899-E1C3B2E85782 Q50914423-ADBC03C2-238D-40E9-8E6D-DC8BC48E0405

P2860

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q43905270

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

@en

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

@nl

type

Item

label

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

@en

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

@nl

prefLabel

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

@en

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

@nl

P1476

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma

@en

P2093

Ascension Lopez-Diaz de Cerio

http://www.w3.org/2001/XMLSchema#string

Helena Villanueva

http://www.w3.org/2001/XMLSchema#string

Mario Martinez Soldevilla

http://www.w3.org/2001/XMLSchema#string

Maurizio Bendandi

http://www.w3.org/2001/XMLSchema#string

Susana Inoges

http://www.w3.org/2001/XMLSchema#string

P2860

Idiotype vaccines for human B-cell malignancies

Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma

Anti-idiotype vaccines for human follicular lymphoma.

Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

Transformation of follicular lymphoma

Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.

Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy.

Variations in "rescuability" of immunoglobulin molecules from different forms of human lymphoma: implications for anti-idiotype vaccine development.

P304

1661-1669

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.11.132

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Fernando Pastor

P577

2011-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22085168

http://www.w3.org/2001/XMLSchema#string

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

about

P2860

P2860

BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698